Camso announces that 24 dealers across America joined its Camso Crushing Cancer 2019 program, raising a total of $144,957 that will be donated to the Pancreatic Cancer Action Network.
The program ran for the months of August and September across Camso’s construction tire and track dealer network in the United States. During this period, on behalf of their dealers, the company donated a portion of the proceeds from the sale of select construction tires to the Pancreatic Cancer Action Network (PanCAN).
“When we launched this program last August, little did we know that we would be able to raise such an important amount for our donation to the Pancreatic Cancer Action Network,” says Jim Donoghue, Director, Marketing and Sales Support – North America at Camso. “Most of us know families who have been affected by this disease, and we are proud to support this cause.”
Camso would like to thank each dealer for their generosity in joining this cause:
- Best One Tire
- Blue Ribbon Tire
- Cassidy Tire
- Commercial Tire
- Dakota Tire
- Gallagher Tire
- Lapps Loader Service
- McCarthy Tire
- Midstate Tire
- Northwest Tire Factory
- Parkhouse Tire
- Pomps Tire
- Quality Tire Company
- Ray’s Tire Service
- Redburn Tire Company
- Royal Tire
- Service Tire and Truck Center
- Southern Tire Mart
- Sullivan Tire
- Tandem Tire
- TF Tire & Service
- Tiresoles Group
- United Tire Center
- Wingfoot
“We are sincerely grateful for this generous gift from Camso and their dealers,” said Brooke Caviglia, PanCAN Associate Director, Community Engagement, “Their support will directly benefit thousands of pancreatic cancer patients and their families and will help in our fight against this deadly disease.”
According to PanCAN, pancreatic cancer is currently the third leading cause of cancer-related death in the United States with a five-year survival rate of just nine percent. Funds raised for PanCAN through the Camso Crushing Cancer 2019 program will advance critical research programs, including PanCAN’s Clinical Trial initiative, Precision PromiseSM, Early Detection Initiative (EDI), precision medicine initiative Know Your Tumor®, additional field research, and other patient advocacy efforts – all to improve patient outcomes.
